Current stage-Stage III Posts on Medivizor
Navigation Menu

Current stage-Stage III Posts on Medivizor

MRI prognostic parameters in tailoring treatment for locally advanced rectal cancer

Posted by on Aug 31, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the use of MRI predictive results to decide the best treatment for patients with locally advanced rectal cancer (LARC). Researchers suggested that early MRI results should be used in the treatment decision making. Some background Colorectal cancer is the third most common cancer in the world. Patients with LARC...

Read More

Looking for patients with advanced melanoma to test a combination of antibody and enzyme drugs

Posted by on Aug 31, 2019 in Melanoma | 0 comments

In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...

Read More

Searching for patients with advanced colorectal cancer to test a new combination therapy

Posted by on Aug 22, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In many...

Read More

Searching for patients with advanced triple-negative breast cancer to test a new combination treatment

Posted by on Aug 22, 2019 in Breast cancer | 0 comments

In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...

Read More

Looking for patients with BRAF positive inoperable colorectal cancer to test a new treatment combination

Posted by on Aug 14, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...

Read More

Waiting at least 8 weeks for surgery after chemoradiotherapy increases rectal cancer response

Posted by on Jul 28, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the best interval time between chemoradiation therapy and rectal cancer surgery for the best outcomes in patients with rectal cancer. Researchers suggested that waiting at least 8 weeks until the surgery increases the tumor response to the treatment. Some background The standard treatment for locally advanced...

Read More

Looking for participants with advanced cancer to test a new therapy

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...

Read More

Durvalumab as third-line treatment in advanced lung cancer – does gene expression affect response?

Posted by on Jul 21, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated if durvalumab (Infinzi) is effective in advanced non-small cell lung cancer (NSCLC) that has progressed on previous therapies.  They found that the response to durvalumab was greatest in patients with high PD-L1 expression. Some background Non-small cell lung cancer (NSCLC) is the most common form...

Read More